⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27491998 | 0.72 | — | — | |
| SCHEMBL9807 | 0.70 | — | — | |
| SCHEMBL996066 | 0.70 | — | — | |
| SCHEMBL8726423 | 0.70 | — | — | |
| SCHEMBL17509540 | 0.70 | — | — | |
| SCHEMBL7113463 | 0.68 | — | — | |
| SCHEMBL1252971 | 0.67 | — | — | |
| SCHEMBL246071 | 0.67 | — | — | |
| SCHEMBL1816998 | 0.67 | — | — | |
| SCHEMBL7858162 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116710450-A | Pyrrolo [3,2-b ] pyridine derivatives for the treatment of cGAS-related disorders | 诺华股份有限公司 | 2023-09-05 | — | — | CN | claimed |
| CN-116635382-A | Indole derivatives useful for treating cGAS-related disorders | 诺华股份有限公司 | 2023-08-22 | — | — | CN | claimed |
| CN-101128413-A | Substituted oxyarenes | BAYER CROPSCIENCE AG (DE) | 2008-02-20 | — | — | CN | claimed |
| CN-115103670-A | Transcription Enhancement Associated Domain (TEAD) transcription factor inhibitors and uses thereof | 达纳-法伯癌症研究所股份有限公司 | 2022-09-23 | — | — | CN | disclosed |
| CN-113444086-A | Ezh2 inhibitor and application thereof | 达纳-法伯癌症研究所股份有限公司 | 2021-09-28 | — | — | CN | disclosed |
| CN-112367991-A | TAIRE family kinase inhibitors and uses thereof | 达纳-法伯癌症研究所股份有限公司 | 2021-02-12 | — | — | CN | disclosed |
| CN-110225895-A | Matrix protective film, attachment prevent component and attachment from preventing the forming method of component | 星和电机株式会社 | 2019-09-10 | — | — | CN | disclosed |
| EP-2970146-B1 | ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR | ABBVIE DEUTSCHLAND (DE) | 2017-11-01 | — | — | EP | disclosed |
| EP-2909201-B1 | ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR | ABBVIE DEUTSCHLAND (DE) | 2017-02-22 | — | — | EP | disclosed |
| US-9388148-B2 | Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor | ABBVIE INC. (US) | 2016-07-12 | — | — | US | disclosed |
| US-9388141-B2 | Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor | ABBVIE INC. (US) | 2016-07-12 | — | — | US | disclosed |
| US-9376396-B2 | Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-06-28 | — | — | US | disclosed |
| CN-102459235-B | Pyrazinyl pyrazoles | BAYER CROPSCIENCE AG | 2015-03-11 | — | — | CN | disclosed |
| US-20140303176-A1 | ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-10-09 | — | — | US | disclosed |
| US-20140275104-A1 | ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-09-18 | — | — | US | disclosed |
| US-20140194437-A1 | ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-07-10 | — | — | US | disclosed |
| WO-2010136145-A1 | PYRAZINYLPYRAZOLES | BAYER CROPSCIENCE AG (DE) | 2010-12-02 | — | — | WO | disclosed |
| CN-101128413-A | Substituted oxyarenes | BAYER CROPSCIENCE AG (DE) | 2008-02-20 | — | — | CN | disclosed |